Edward Hurwitz

Edward Hurwitz serves as a Managing Director at MPM Capital. He is a Board Member of Dyne Therapeutics. He is an Angel Investor. He brings to this role a track record of overseeing innovative investment funds, sourcing investment opportunities and working with portfolio companies to develop innovative products and exceed financial goals. He was most recently Founder and Managing Director of Precision BioVentures LLC where he focused on developing novel investment strategies and building a portfolio of businesses. While there, he co-founded Viewpoint Therapeutics, an innovative ophthalmology company. Prior to this, he was a Director of two funds at Alta Partners - Alta BioPharma Management III and Alta Partners Management VIII. He is currently a Boards Member of Applied Genetic Technologies Corporation, Macrogenics, Inc. and Viewpoint Therapeutics. While at Alta, he also led investments and is a Board Member of Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer) and Taligen Therapeutics (acquired by Alexion). Over the course of his career, he has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier and a biotechnology research analyst for both Robertson Stephens and Company and Smith Barney Shearson.